Data Sheet (Cat.No.T6916)

TargetMol

OICR-9429

Chemical Properties



CAS No. : 1801787-56-3

Formula: C29H32F3N5O3

Molecular Weight: 555.59

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukemia cells in vitro.
Targets(IC50)	Apoptosis,Histone Methyltransferase,JAK
In vitro	OICR-9429 binds WDR5 with high affinity (Kd=93±28 nM) and competitively disrupts its interaction with a high-affinity Wdr5-interacting (WIN) peptide of MLL (Kdisp=64±4 nM) [1].
Kinase Assay	AR binding affinity: AR binding affinities of test compounds are studied in cytosolic lysates obtained from ventral prostates of castrated rats by a competition binding assay. Fresh prostates are minced and homogenized with Buffer A containing protease inhibitors. The homogenates are centrifuged and the resultant supernatants are treated with a dextran-coated charcoal solution to remove endogenous steroids. The dissociation constant of the radio ligand [3H]mibolerone for isolated rat ARs is determined in a saturation binding experiment. For the determination of Ki values, prostate cytosol preparations and 1?nM [3H]mibolerone are incubated with increasing concentrations of test compounds overnight. After the incubation, bound and free steroids are separated by treatment with 100?µL of dextran-coated charcoal suspension. Bound radioactivity is determined by counting 100?µL of supernatant fraction in 200?µL of scintillation fluid using a microbeta counter. All procedures are
Cell Research	20,000 viable, actively proliferating primary human AML cells per well were seeded in 96-well plates in triplicates and treated with 0.05% DMSO or OICR-9429. Cell viability was measured using the Cell Titer-Glo luminescent cell viability assay on a VICTOR X4 luminometer after 72 h.(Only for Reference)

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 100 mg/mL (179.99 mM),Sonication is recommended. Ethanol: 12 mg/mL (21.6 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.6 mM),Sonication is recommended.

In vivo Formulation	*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7999 mL	8.9994 mL	17.9989 mL
5 mM	0.360 mL	1.7999 mL	3.5998 mL
10 mM	0.180 mL	0.8999 mL	1.7999 mL
50 mM	0.036 mL	0.180 mL	0.360 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Grebien F, et al. Nat Chem Biol. 2015, 11(8):571-8.
Yuan J, Peng H, Mo B, et al. Inhibition of Wdr5 Attenuates Ang-II-Induced Fibroblast-to-Myofibroblast Transition in Cardiac Fibrosis by Regulating Mdm2/P53/P21 Pathway. Biomolecules. 2022, 12(11): 1574.
Ye L, Shen S, Mao Q, et al.Nuclear-localized HKDC1 promotes hepatocellular carcinoma through phosphorylating RBBP5 to upregulate H3K4me3.Cell Reports.2025, 44(2).